IHT Wealth Management LLC trimmed its position in AstraZeneca PLC (NASDAQ:AZN) by 10.8% during the 1st quarter, Holdings Channel.com reports. The fund owned 14,903 shares of the company’s stock after selling 1,799 shares during the period. IHT Wealth Management LLC’s holdings in AstraZeneca were worth $741,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Concord Wealth Partners acquired a new position in shares of AstraZeneca in the 4th quarter valued at $34,000. IronBridge Private Wealth LLC acquired a new position in shares of AstraZeneca in the 4th quarter valued at $35,000. Atlas Private Wealth Advisors increased its position in shares of AstraZeneca by 117.3% in the 1st quarter. Atlas Private Wealth Advisors now owns 754 shares of the company’s stock valued at $38,000 after acquiring an additional 407 shares during the period. Jackson Grant Investment Advisers Inc. acquired a new position in shares of AstraZeneca in the 4th quarter valued at $38,000. Finally, Allred Capital Management LLC acquired a new position in shares of AstraZeneca in the 1st quarter valued at $39,000. 15.63% of the stock is currently owned by hedge funds and other institutional investors.
AZN stock opened at $57.77 on Thursday. The stock’s 50-day moving average price is $57.99. The company has a debt-to-equity ratio of 1.21, a quick ratio of 0.67 and a current ratio of 0.87. AstraZeneca PLC has a 52-week low of $46.48 and a 52-week high of $60.93. The stock has a market cap of $151.62 billion, a price-to-earnings ratio of 25.02, a P/E/G ratio of 1.18 and a beta of 0.56.
Several brokerages have weighed in on AZN. Argus reaffirmed a “hold” rating on shares of AstraZeneca in a research report on Monday, April 19th. Citigroup reaffirmed a “buy” rating on shares of AstraZeneca in a research report on Wednesday. SVB Leerink cut their price target on AstraZeneca from $64.00 to $63.00 and set an “outperform” rating on the stock in a research report on Friday, July 16th. Finally, UBS Group reaffirmed a “buy” rating on shares of AstraZeneca in a research report on Thursday, June 17th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and eleven have given a buy rating to the company’s stock. AstraZeneca has a consensus rating of “Buy” and an average target price of $99.00.
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases.
Recommended Story: Outstanding Shares and The Effect on Share Price
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca PLC (NASDAQ:AZN).
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.